Clinical Trials Directory

Trials / Terminated

TerminatedNCT00313092

Obstructive Sleep Apnea Syndrome in Glaucoma

Does Plasma Matrix-metalloproteinase Activity Predict Glaucomas in Patients With OSAS (Obstructive Sleep Apnea Syndrome) and Does the Level of Plasma Matrix-metalloproteinase Activity Decrease After One Month of nCPAP-treatment

Status
Terminated
Phase
Study type
Observational
Enrollment
60 (actual)
Sponsor
Selim Orguel · Academic / Other
Sex
All
Age
18 Years – 95 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with OSAS and if the level of plasma matrix-metalloproteinase activity will decrease after one month of nCPAP-treatment.

Detailed description

Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The key feature of glaucoma is damage to the optic nerve head, which is not necessarily related to an increased intraocular pressure. The prevalence of glaucoma among the patients with sleep apnoea was 7,2%: normal-tension glaucoma 2,9%, primary open-angle glaucoma 4,3%. The prevalence of obstructive sleep apnoea syndrome (OSAS) is around 4-10% for men and 2-4% for women. Matrix metalloproteinases (MMPs) substrates include essentially all extracellular matrix components as well as a wide array of molecules involved in intracellular adhesion, cell-matrix interaction, and cell signalling. However, MMPs effects are not restricted to extracellular matrix degradation. The prevalence of increased MMP in patients with OSAS and its predicting value for an additional glaucoma are not known. Further, we do not know if treatment of OSAS with nasal continuous positive air pressure(nCPAP) can decrease the MMP activity. With this study, we want to determine the prevalence of MMP activity and the prevalence of glaucoma in patients with OSAS. Further, we want to investigate if a nCPAP treatment period of four weeks decreases the MMP activity.

Conditions

Interventions

TypeNameDescription
DEVICEnCPAP treatmenttreatment with positive air pressure during night

Timeline

Start date
2005-01-01
Primary completion
2005-09-01
Completion
2005-09-01
First posted
2006-04-11
Last updated
2015-10-02

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT00313092. Inclusion in this directory is not an endorsement.